Week 1: 1,767 Studies and Counting
Weekly Digest β Week 1
Welcome to the first edition of our weekly research digest! Here is what happened in psychedelic research this week.
By the Numbers
Top Findings
Psilocybin for Treatment-Resistant Depression A new open-label study from Imperial College London demonstrated significant and sustained improvements in depressive symptoms following two psilocybin sessions. The mean MADRS score decreased by 62% at the 6-week follow-up.
MDMA-Assisted Therapy Phase 3 Update The final Phase 3 trial data for MDMA-assisted therapy for PTSD continues to be analyzed. Early signal suggests strong effect sizes consistent with previous phases.
Ketamine Dosing Optimization Researchers at Yale published new findings on optimal ketamine dosing protocols, suggesting that lower-frequency maintenance sessions may be equally effective as current weekly protocols.
Trending Substances
Coming Next Week
We are finalizing our AI-powered study summarization pipeline, which will automatically generate English and German summaries for every new study added to the database. Stay tuned!
Share this post